Market: NASD |
Currency: USD
Address: 3950 Johns Creek Court
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Show more
📈 Femasys Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.67
-
Upside/Downside from Analyst Target:
1,487.30%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
50-100%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Femasys Inc.
Date | Reported EPS |
---|
2025-08-08 | -0.16 |
2025-05-08 | -0.23 |
2025-03-27 | -0.23 |
2024-11-12 | -0.24 |
2024-08-08 | -0.21 |
2024-05-09 | -0.17 |
2024-03-28 | -0.19 |
2023-11-14 | -0.26 |
2023-08-10 | -0.22 |
2023-05-11 | -0.25 |
2023-03-30 | -0.24 |
2022-11-10 | -0.25 |
2022-08-10 | -0.22 |
2022-05-11 | -0.24 |
2022-03-24 | -0.08 |
📰 Related News & Research
No related articles found for "femasys inc".